Cargando…

The Topical Nanodelivery of Vismodegib Enhances Its Skin Penetration and Performance In Vitro While Reducing Its Toxicity In Vivo

Vismodegib is a first-in-class inhibitor for advanced basal cell carcinoma treatment. Its daily oral doses present a high distribution volume and several side effects. We evaluated its skin penetration loaded in diverse nanosystems as potential strategies to reduce side effects and drug quantities....

Descripción completa

Detalles Bibliográficos
Autores principales: Calienni, Maria Natalia, Maza Vega, Daniela, Temprana, C. Facundo, Izquierdo, María Cecilia, Ybarra, David E., Bernabeu, Ezequiel, Moretton, Marcela, Alvira, Fernando C., Chiappetta, Diego, Alonso, Silvia del Valle, Prieto, María Jimena, Montanari, Jorge
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7912039/
https://www.ncbi.nlm.nih.gov/pubmed/33535434
http://dx.doi.org/10.3390/pharmaceutics13020186
Descripción
Sumario:Vismodegib is a first-in-class inhibitor for advanced basal cell carcinoma treatment. Its daily oral doses present a high distribution volume and several side effects. We evaluated its skin penetration loaded in diverse nanosystems as potential strategies to reduce side effects and drug quantities. Ultradeformable liposomes, ethosomes, colloidal liquid crystals, and dendrimers were able to transport Vismodegib to deep skin layers, while polymeric micelles failed at this. As lipidic systems were the most effective, we assessed the in vitro and in vivo toxicity of Vismodegib-loaded ultradeformable liposomes, apoptosis, and cellular uptake. Vismodegib emerges as a versatile drug that can be loaded in several delivery systems for topical application. These findings may be also useful for the consideration of topical delivery of other drugs with a low water solubility.